Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
Oversubscription means eligible auction and purchase-price participants are expected to sell approximately 55 percent of their tendered shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arbutus Biopharma (ABUS) announced preliminary tender-offer results and expects to purchase common shares for cancellation totaling US$230 million. The offer expired September 29, 2026. The expected purchase is 46,000,000 shares at US$5.00 each, excluding fees and expenses, representing approximately 23 percent of shares outstanding that day. Arbutus anticipates approximately 153,275,907 shares outstanding after completion.
The offer was oversubscribed, with 65,907,215 shares tendered through eligible auction and purchase-price tenders. Arbutus expects approximately 55 percent of those tendered shares to be purchased, except odd lots, which avoid proration. Another 9,307,231 shares are anticipated to be purchased through proportionate tenders. Roivant will maintain approximately 19.5% ownership. Results remain preliminary, subject to depositary verification and timely delivery of shares tendered through guaranteed delivery.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Expected capital return of US$230 million buys 46,000,000 shares for cancellation at US$5.00 each, approximately 23 percent of outstanding shares. 25% of market cap
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Oversubscribed offer limits expected purchases to approximately 55 percent of eligible auction and purchase-price tenders, excluding odd lots.
- Minor point. Forward-looking: it has not happened yet and may not happen.Auction tenders above US$5.00 per share are not expected to be purchased.
- Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary results require depositary verification and assume guaranteed-delivery shares arrive within the one trading-day settlement period.
Key Figures
- Aggregate purchase price
- US$230 million
- Preliminary expected total, excluding fees and expenses
- Purchase price
- US$5.00 per Share
- Preliminary price; above ABUS's US$4.69 Sept. 29 prior close
- Shares expected to be purchased
- 46,000,000 Shares
- Preliminary expected take-up under the Offer
- Validly tendered shares
- 65,907,215 Shares
- Preliminary count tendered at or below the Purchase Price and through purchase price tenders
- Estimated proration
- Approximately 55%
- Expected portion of eligible tendered Shares purchased
- Proportionate tenders
- 9,307,231 Shares
- Anticipated purchases from the separate pool, not subject to proration
- Expected post-offer shares outstanding
- Approximately 153,275,907 Shares
- Anticipated immediately following completion
Historical Context
-
Launched the same offer with a US$230 million cap and a US$5.00–US$5.75 tender range.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
modified dutch auction financial
proration financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US
In accordance with the terms and conditions of the Offer and based on the preliminary calculation of TSX Trust Company, as depositary for the Offer (the “Depositary”), Arbutus expects to take up and pay for 46,000,000 Shares at a price of US
Based on the preliminary calculation of the Depositary, 65,907,215 Shares were validly tendered and not properly withdrawn pursuant to auction tenders at or below the Purchase Price and pursuant to purchase price tenders. Since the Offer was oversubscribed, shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders will have the number of Shares purchased prorated following the determination of the final results of the Offer (other than “odd lot” tenders, which are not subject to proration). Arbutus currently expects that shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders will have approximately 55 percent of their tendered Shares purchased by Arbutus. Shareholders who made auction tenders at a price in excess of the Purchase Price should not expect to have any of those Shares purchased by Arbutus. 9,307,231 Shares are anticipated to be taken up and purchased pursuant to proportionate tenders, which are purchased in a separate pool and are not subject to proration.
Roivant Sciences Ltd., the beneficial owner of 38,847,462 Shares, approximately
The number of Shares expected to be purchased, the estimated proration factor, the number of Shares expected to remain outstanding after completion of the Offer and the Purchase Price referred to above are preliminary, remain subject to verification by the Depositary, and are based on the assumption that all Shares tendered through notice of guaranteed delivery will be delivered within the one trading-day settlement period. Following take-up and payment for Shares purchased under the Offer, Arbutus will issue a press release announcing the final results, including the final proration factor and the final Purchase Price.
Promptly after such press release, payment for the Shares accepted for purchase will be made in accordance with the terms of the Offer and applicable law, and the Depositary will return all other Shares tendered and not purchased.
The full details of the Offer are described in the offer to purchase and issuer bid circular dated August 24, 2026, as well as the related letter of transmittal and notice of guaranteed delivery, copies of which were filed and are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
This news release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Shares.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is currently developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for the treatment of chronic hepatitis B infection. The Company is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of on-going lawsuits against Pfizer/BioNTech for use of Arbutus’ patented LNP technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains “forward-looking statements,” including statements regarding the completion of the Offer, the amount and pricing of the tender offer, the number of Shares expected to be issued and outstanding following completion of the Offer, the anticipated proration to occur in connection with the Offer, the number of Shares to be taken up and paid for pursuant to valid tenders in the Offer, Roivant Sciences Ltd.’s anticipated holdings following completion of the Offer, further communication regarding completion of the Offer, payment for Shares in accordance with the Offer, the return of Shares not purchased and other terms and conditions of the Offer, which involve known and unknown risks, uncertainties and other factors that may cause actual results and other events to be materially different from those expressed or implied by such forward-looking statements.
The forward-looking statements contained in this press release are subject to a number of material factors that could cause actual results to differ materially, including, the impact of Shares tendered through notice of guaranteed delivery, the satisfaction of the conditions to completion of the Offer, developments or changes in general economic or market conditions, developments or changes in the securities markets, developments or changes in our business, financial condition or cash flows, as well as other risks detailed in our Annual Report on Form 10-K for the most recent fiscal year as filed with the SEC.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K for the most recent fiscal year as filed with the SEC, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sec.gov and at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus undertakes no obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Arbutus Biopharma Corporation ir@arbutusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.